Get the Stockscreener App
1.80
3.75%
+0.065
Aadi Bioscience Inc stock is currently priced at $1.80, with a 24-hour trading volume of 183.78K.
It has seen a +3.75% increased in the last 24 hours and a -6.25% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.74 pivot point. If it approaches the $1.81 resistance level, significant changes may occur.
Previous Close:
$1.735
Open:
$1.74
24h Volume:
183.78K
Market Cap:
$44.20M
Revenue:
$23.26M
Net Income/Loss:
$-63.41M
P/E Ratio:
-0.7377
EPS:
-2.44
Net Cash Flow:
$-64.56M
1W Performance:
-2.17%
1M Performance:
-6.25%
6M Performance:
-65.78%
1Y Performance:
-77.50%
1D Range:
$1.715
$1.81
52W Range:
$1.55
$8.49
Aadi Bioscience Inc Stock (AADI) Company Profile
Name
Aadi Bioscience Inc
Sector
Industry
Phone
424 473 8055
Address
17383 Sunset Boulevard, Suite A250, Pacific Palisades
Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
Aadi Bioscience Inc Stock (AADI) Latest News
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Drop in Short Interest - Defense World
Defense World
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Drop in Short Interest - Defense World
Defense World
Investor's Delight: Aadi Bioscience Inc (AADI) Closes Weak at 1.76, Down -6.38 – DWinneX - The Dwinnex
The Dwinnex
Aadi Bioscience to Participate in the Jefferies Healthcare Conference - PR Newswire
PR Newswire
Aadi Bioscience Inc (AADI) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
The InvestChronicle
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - br.ADVFN.com
br.ADVFN.com
Aadi Bioscience Inc Stock (AADI) Financials Data
Aadi Bioscience Inc (AADI) Revenue 2024
AADI reported a revenue (TTM) of $23.25 million for the quarter ending September 30, 2023, a +111.62% rise year-over-year.
Aadi Bioscience Inc (AADI) Net Income 2024
AADI net income (TTM) was -$63.41 million for the quarter ending September 30, 2023, a -1.31% decrease year-over-year.
Aadi Bioscience Inc (AADI) Cash Flow 2024
AADI recorded a free cash flow (TTM) of -$64.56 million for the quarter ending September 30, 2023, a -27.20% decrease year-over-year.
Aadi Bioscience Inc (AADI) Earnings per Share 2024
AADI earnings per share (TTM) was -$2.36 for the quarter ending September 30, 2023, a +20.81% growth year-over-year.
About Aadi Bioscience Inc
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, ABI-009 (FYARRO) is a form of sirolimus bound to albumin. Aadi is evaluating ABI-009 in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was founded in 2011 and is headquartered in Pacific Palisades, California.
0.79%
3.50%
Cap:
|
Volume (24h):